Oncotarget不被MEDLINE收录，Pubmed上就搜不到了？
我的图书馆
Oncotarget不被MEDLINE收录，Pubmed上就搜不到了？
作者：叶子近日，备受中国医学研究人员“喜爱”的四大神刊之一的Oncotarget已经确认不再被MEDLINE收录。作为PMOS之一（Plos One，Medicine，Oncotarget和Scientific Reports），之前就已经有很多高校和医院把它们列入了科研黑名单，在上面发表文章不能报销版面费、没有科研奖励、升职称也不算，还有些在基金申请中还会当做负面因素。这次Oncotarget虽然还是属于SCI期刊只是不再被MEDLINE索引（日后）。有人认为，MEDLINE不再索引后，Pubmed上就搜不到了。Pubmed作为生命科学和医学领域最常用的搜索引擎之一，剔除后会极大的影响文章的被引次数，也会导致后续两年的Oncotarget的影响因子水平下降，之后SCI还要不要它就只有天知道了。真的是这样么？看这张图，根据Pubmed上检索出的结果可以看到，MEDLINE在8月30日后就不收录了，但Pubmed上还是有的。很多人认为Pubmed=MEDLINE，其实是MEDLINE只是Pubmed的最大来源，也就是说Pubmed也收录了很多MEDLINE以外的期刊。比如Oncotarget现在有些文章还是被PMC(PubMed central)收录的，也就能用Pubmed查到，而且都是免费全文，三者关系看图就明白的。就目前来看，Oncotarget并无明显违规行为（如SCI最重视的自引率仅为25%）。MEDLINE给出的剔除理由是，近年Oncotarget的出版形式、文章质量和编辑过程发生了重大变化，所有权和发行人也发生了改变。Oncotarget作为一本OA期刊，一开始是专注于肿瘤学的研究，但现在正往水刊的方向越走越远。不但接受了越来越多的生命科学领域的相关论文，包括神经科学，内分泌学，心脏病学等等都有涉猎。另外，它们还缩短了出版周期，现在是每周出版两期，去年总共发表了多达6625篇论文，引发了大量的争议。而且它的版面费还贼贵，从之前的2850美元，上涨到了3400美元。简单一算，期刊去年就捞了525000，美元！因为以上原因，Oncotarget虽然在国内饱受诟病，但国外并无该争议，毕竟主编是位很牛的人物。Oncotarget今年的影响因子相比去年也有小幅上升（5.1657），但相比前几年6分 的时代下滑了不少。如果这种情况在短时间内不能逆转，愿意将科研结果提交给Oncotarget的研究人员也会越来越少，由此看来，MEDLINE的剔除将会对Oncotarget造成巨大的损失。期刊被MEDLINE收录与否为什么对科研人员这么重要呢？在投稿的时候肯定先要对期刊的情况进行一番了解，包括主要研究内容啊，出版周期啊，每年发文量啊。这些重要的数据在Pubmed上都能很方便的看到，而如果将论文提交给没有在MEDLINE索引的期刊上，很多文章就不能被PubMed搜索到，也可能会让其他研究人员找不到你的研究成果，从而对职业产生负面影响。那怎么快速查到一个期刊是不是被MEDLINE剔除了？很简单，在Pubmed里的NLM Catalog栏目下搜索“all[filter] NOT currentlyindexed[all] AND xxxx”，这个xxxx就是你要查的期刊名，比如要看Oncotarget是不是真的被踢了，如下图输入就可以了。欢迎投稿.cn合作微信：helixlife6
TA的最新馆藏
喜欢该文的人也喜欢||||||||||||||||||||||||||||||
Oncotarget
Oncotarget
影响因子：
出 版 社：
Impact Journals
出 版 地：
Albany, N.Y.
出版国家：
United States
刊　　期：
创刊时间：
语　　种：
审稿周期：
偏慢,4-8周
中科院分区：
投稿命中率：
国外数据库收录：
中国收录文章数：
5年影响因子：
研究领域：
官方链接：
投稿须知：
期刊介绍：
Oncotarget&publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy and new therapeutic strategies.
&&&&&&&&&&
&&&&&&&&&&
全站分类导航
|||||||||||||||
|||||||||||||||
||||||||||||
版权所有& CopyRight , , All Rights ReservedOncotarget被MEDLINE “踢出”是否影响PubMed及SCI收录
已有 7185 次阅读
|系统分类:
美捷登Mike近来有网友称自己8月份发表在Oncotarget 杂志上的文章，接受后一开始还可以在PubMed上查到，最近再次查询时出现显示错误。随后联系杂志，被告知是PubMed的技术问题导致的[1]。不过笔者在NCBI上仔细查询后发现，Oncotarget 刚刚被MEDLINE“踢出”（图1），收录截止到今年7月25日的第8卷30期。图1. Oncotarget杂志MEDLINE收录信息之前Oncotarget 回复网友咨询时提及PubMed技术问题解决后该杂志接受的稿件都会被PubMed收录，不知道此消息是否准确。不过查询Oncotarget 的PMC（PubMed Central）收录情况，目前收录到今年8月8日的第8卷32期，好像也出现了拖延（图2）。若是期刊接受发表的稿件有质量问题，那就很可能不单单是被MEDLINE“踢出”，也是有可能被PubMed“踢出”。图2.Oncotarget杂志PMC收录信息PubMed是目前最常用的期刊文章检索数据库。该检索数据库包括MEDLINE、PMC，以及NCBI Book Shelf收录的图书。所以，MEDLINE数据库只是PubMed检索数据库的一部分。经常有网友问，期刊被PubMed或MEDLINE“踢出”后是不是也会被SCI“踢出”，答案是No。这是因为PubMed/MEDLINE与SCI收录评估标准不同。同样的，很多被SCI“踢出”的或者非SCI期刊仍然还被PubMed或者MEDLINE收录。一个很好的例子就是International Journal of Clinical and Experimental Medicine(IJCEM)杂志。IJCEM杂志2016年4月份发邮件通知所有作者，该杂志被PubMed延期收录一年[2]。事实上，IJCEM只被PubMed收录到2015年12月底（图3）。图3. IJCEM杂志PubMed收录信息目前，IJCEM 投稿系统中仍会提醒投稿作者：此杂志只能等到2019年6月才能重新申请PubMed收录，而不止是之前IJCEM通知自己作者的“延期收录一年”[2]。但是IJCEM去年6月和今年6月的文章仍然收录在SCI数据库中（图4）。另外PubMed收录和MEDLINE收录也是有不同的标准和要求，只不过MEDLINE收录的要求比PubMed收录要求高一些。总之，被其中一个收录数据库“踢出”并不意味着一定也会被其它数据库“踢出”。图4. IJCEM杂志SCI收录信息参考文献：1. /bbs/topic/?keywords=oncotarget2. 一点之见即可成文，e-Century 出版社的两个杂志IJCEP和IJCEM 的文章将被PuMbed延迟1年收录. 丁香园.———————————————————————— ——————
转载本文请联系原作者获取授权，同时请注明本文来自美捷登科学网博客。链接地址：
上一篇：下一篇：
当前推荐数：2
评论 ( 个评论)
扫一扫，分享此博文
作者的精选博文
作者的其他最新博文
热门博文导读
Powered by
Copyright &Online ISSN:
Oncotarget
Assistant Editor
English Editor
Production editor
Impact Journals, LLC meets the Wellcome Trust Publisher Requirements, and is now a member of the
Editors-in-Chief
Andrei V. Gudkov,
PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Cancer Institute (RPCI), Buffalo, NY
His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.
Mikhail V. Blagosklonny, M.D., Ph.D., Professor, Roswell Park Cancer Institute, Buffalo, NY
Dr. Blagosklonny is the author of over 250 articles in peer-reviewed journals. He has served as Associate Editor of
Cancer Res,
Cell Death Differ,
Cancer Biol Ther,
Autophagy,
Int J Cancer,
Am J Pathology,
PLOS ONE and as Editor-in-Chief of
Cell Cycle. His research interests range from molecular and cellular biology to clinical investigations. Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.
Editorial Board
Cory Abate-Shen, PhD, Professor, Director of Research, Department of Pathology, Associate Director, Herbert Irving Comprehensive
Cancer Center, Columbia University, NY
Frederick W. Alt, Ph.D., member of the National Academy of Sciences, Professor, Harvard Medical School
Dr. Alt is also Investigator, Howard Hughes Medical Inst., Charles A. Janeway Professor of Pediatrics, HMS, Scientific Director, CBRI Institute for Biomedical Research.Fred Alt received a PhD from the Department of Biological Sciences at Stanford University.
He is a Howard Hughes Medical Institute investigator, a member of the National Academy of Sciences and the American Academy of Sciences.
He is the recipient of He is the recipient of the 2003 Excellence in Mentoring Award from the American Association of Immunologists and the 2004 Clowes Memorial Award from the American Association of Cancer Research.
Editorial Boards:
Mol. and Cell. Biology;
Advances in Immunology;
International Immunology;
J. Exp. Med.;
Current Opinion in Immunology;
Immunity (founding Co- 1993-present);
Molecular Medicine (C 1997-present);
Faculty of 1000 (co-head, Immunology). Honors and Awards: Fox Award, Stanford Univ. (1973); Hirschl Award (1983); Searle S (1983) Mallinckrodt S (1984); NIH Merit Award (1991); National Academy of Sciences (1994); American Academy of Microbiology (1994); American Academy of Arts and Sciences (1994); Associate (Foreign) Member, European Molecular Biology Organization (1999); Excellence in Mentoring Award,Association of Immunologists (2003); American Association of Cancer Research B.H.A. Clowes Award (2004); Rabi Shai Shacknai Memorial Prize in Immunology & Cancer Research (2005); Leukemia & Lymphoma Society de Villiers International Achievement Award (2005), Pasarow Foundation Prize in Cancer Research (2005); Irvington Institute Scientific Leadership in Immunology Award (2005); Establishment of Frederick W. Alt Award for New Discoveries in Immunology by the Irvington Institute (2006); National Cancer Institute Alfred Knudson Award in Cancer Genetics(2007).
Dario Altieri, MD, Robert and Penny Fox Distinguished Professor, Director, The Wistar Institute Cancer Center, Executive Vice President, Chief Scientific Officer, The Wistar Institute, Philadelphia, PA.
Dafna Bar-Sagi, Ph.D., Professor and Chair, Department of Biochemistry New York University School of Medicine, 550 First Avenue New York, NY 10016
After earning her undergraduate and master's degree in Biochemistry from Bar-Ilan University in Israel, Dr. Bar-Sagi completed a PhD in Cell Biology at the State University of New York, Stony Brook (SUNY). She received postdoctoral training and eventually served as Senior Staff Investigator at Cold Spring Harbor Laboratory in Long Island. In 1995, she joined the faculty of the Department of Molecular Genetics and Microbiology at SUNY and served as Department Chair from . She relocated to New York University Medical Center in 2006, where she is currently Professor and Chair of the Department of Biochemistry. Dr. Bar-Sagi has published over 100 peer-reviewed articles in leading scientific journals. In 2008, she was appointed Chair of the Scientific Advisory Board of the Pancreatic Cancer Action Network.
Jiri Bartek, MD., Ph.D., Professor,
Head, Department of Cell Cycle and Cancer Danish Cancer Society, Deputy Director, Centre for Genotoxic Stress Research Cancer Institute of Cancer Biology, Copenhagen
He received his M.D. degree from Palacky University in Olomouc, and his Ph.D. degree in Cell Biology from the Institute of Molecular Genetics in Prague, Czech Republic. His main research interests include the molecular mechanisms of mammalian cell-cycle control and responses to DNA damage, and the cancer-predisposing aberrations of these regulatory pathways.
Jiri Bartek has a total of more than 320 publications in peer reviewed journals (about 30-40 in Nature, Science and Cell), with over 26.000 citations. He is currently member of the editorial boards of 10 high-medium impact biomedical journals and has won a number of awards including: () Czech Medical Association Award, (2000) Elected EMBO member, (2002) A. Benzon Prize, (2003) Novo Nordisk Prize, (2003) G.J. Mendel Medal, (2006) Danish Cancer Society Prize
Stephen B. Baylin, M.D., Professor,
Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Virginia and DK Ludwig Professor of Oncology, Baltimore, MD, USA
Dr. Stephen B. Baylin is professor of oncology and medicine, director of the cancer biology program at the oncology center, and the Virginia and D.K. Ludwig Professor of Cancer Research at The Johns Hopkins University School of Medicine, and the associate director for research at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr. Baylin has been a member of committees of the American Cancer Society and the National Institutes of Health, and his multiple honors include a Research Career Development Award from the National Institutes of Health. For the last 20 years, Dr. Baylin has studied the role of epigenetic gene silencing in the initiation and progression of human cancer.
Joseph R. Bertino, M.D., Professor of Medicine and Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School
He has been an American Cancer Society professor since 1976. From 1973 to 1986, Dr. Bertino served as director of the Yale Comprehensive Cancer Center, including director of the center and associate director for clinical research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma. Dr.Bertino has received several awards and honors, including the Rosenthal Award from the American Association of Clinical Research, the Karnofsky Award from the American Society for Clinical Oncology, and the American Cancer Society Medal of Honor. He was the founding editor of the Journal of Clinical Oncology. Currently, he is the associate editor for Cancer Research and Clinical Cancer Research and also the editor of the Encyclopedia of Cancer. Dr. Bertino served as president for the American Society of Clinical Oncology in 1976, and president of the American Association for Cancer Research in 1995-96. Dr. Bertino is the author and co-author of more than 400 scientific publications.
Mina J. Bissell, PhD, member of the National Academy of Sciences, Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkley, CA
Mina Bissell has been recognized for her lifetime contributions to the fields of breast cancer research, the enhanced role of extracellular matrix (ECM) and the nucleus environment to gene expression in normal and malignant tissues. These works have ushered and have changed some central paradigms that have strengthened the importance of context in the development of cancer.
Bruce R. Blazar, M.D., Professor, University of Minnesota, Minneapolis MN
Bruce R. Blazar
is a Regents Professor of Pediatrics, and Chief of the Pediatric Blood and Marrow Transplantation Program. Dr. Blazar is the Director of the University of Minnesota's Clinical and Translational Science Institute.
Kenneth Cowan, M.D., Ph.D., Professor,
University of Nebraska Medical Center, Omaha, NE,
Director, Eppley Institute, Director, UNMC Eppley Cancer Center.
Dr. Cowan has authored more than 240 papers for scientific journals and has been appointed by President Bush to a six-year term on the National Cancer Advisory Board to help shape cancer policy.
Carlo M. Croce, MD, Professor, member of the National Academy of Sciences, Director of Comprehensive Cancer Center, Chair, Molecular Virology, Immunology & Medical Genetics, The Ohio State University, Columbus, OH
Chi Van Dang, M.D., Ph.D. Professor, Vice Dean for Research, the Johns Hopkins University School of Medicine, Baltimore, MD
Dr. Dang has written more than 200 scientific papers. He is senior editor of Cancer Research and serves on the editorial boards of eight other scientific publications, including the Journal of Molecular Medicine, Current Cancer Therapy Reviews, Drug Discovery Today: Disease Mechanisms, Journal of Clinical Investigations, Neoplasia, Clinical and Translational Science and The Vietnamese Medical Journal. Elected to the National Academy of Sciences' Institute of Medicine in 2006, Dr. Dang has received the National Institutes of Health/National Cancer Institute MERIT award and numerous other accolades.
Ronald A. DePinho, President, The University of Texas MD Anderson Cancer Center,
MD, Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
His recent Awards includes Albert Szent-Gyrgyi Prize for Progress in Cancer Research, 2009; Helsinki Medal, 2007; Albert Einstein College of Medicine Distinguished Alumnus Award, 2004; American Cancer Society Edith A. Pistorino Research Professorship, 2004; Member, Institute of Medicine of the National Academies, 2004; AACR-G.H.A. Clowes Memorial Award, 2003
Brian J. Druker, MD, PhD, member of the National Academy of Sciences, Professor, Oregon Health & Science University, Director, OHSU Knight Cancer Institute, Oregon Health & Science University
Dr. Druker is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of Chronic Myeloid Leukemia. Dr. Druker is an investigator of Howard Hughes Medical Institute (HHMI), and was elected to the Institute of Medicine of National Academies in 2003, the American Association of Physician in 2006, and the National Academy of Sciences in 2007.
Wafik S. El-Deiry, M.D., Ph.D. Professor of Medicine, Chief, Hematology/Oncology Rose Dunlap Division Chair in Hematology/Oncology, Associate Director for Translational Research, Cancer Institute, Penn State Hershey Cancer Institute, Hershey, PA
Wafik S. El-Deiry is also an American Cancer Society Research Professor, the Rose Dunlap Professor of Medicine. He is among the top most-cited researchers. His paper, "WAF1, a potential mediator of P53 tumor suppression" (Cell, 75[4]: 817-25, 19 November 1993) is among the top 10 most-cited papers of the 1990s. He is Editor-in-Chief of Cancer Biology and Therapy
Michael A. Dyer, PhD, Professor/Member, St. Jude Faculty
Co-Leader, Developmental Therapeutics for Solid Malignancies Program
Andrew Feinberg, MD, MPH, King Fahd Professor of Molecular Medicine
Department of Medicine, Department of Oncology and Department of Molecular Biology & Genetics, Johns Hopkins University School of Medicine
Dean W. Felsher, MD, PhD,
Stanford University School of Medicine, Stanford, CA
Antonio Giordano, MD, Ph.D, Professor and Director, Sbarro Institute for Cancer Research and Molecular Medicine, Temple
University, Philadelphia, PA
He has published over 350 papers on his work in the fields of cell cycle, gene therapy and the genetics of cancer. Giordano has been named a Knight of the Republic of Italy for outstanding achievements in cancer research. In September of 2009, Giordano received the Philip Mazzei "The Bridge" Award from The American University of Rome for his scientific and economic contributions to the United States and Italy. In the past three years, Dr. Giordano's work has been profiled in Philadelphia Magazine, Philadelphia Business Journal, and Science.
President & CEO of Roswell Park Cancer Institute, the Wallace Family Chair in Translational Research, and Professor of Oncology.
William G. Kaelin Jr., MD, member of the National Academy of Sciences, Professor of Medicine, Harvard Medical School
Kaelin is a 2010 Canada Gairdner International Award Recipient. He is a Howard Hughes Medical Investigator since 1998, a member of the American Society of Clinical Investigation and the American College of Physicians. He recently served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board.
He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center, the Richard and Hinda Rosenthal Prize from the AACR, and a Doris Duke Distinguished Clinical Scientist award. In 2007 he was elected to the Institute of Medicine and in 2010 he was elected to the National Academy of Sciences.
Michael Karin, Ph.D, member of the National Academy of Sciences, Professor of Pharmacology at the University of California, San Diego (UCSD; La Jolla, CA)
Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society, The Herman Beerman Lectureship from the Society of Investigative Dermatology, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin, The Grossman Lectureship form the American Gastroenterology Association and an American Cancer Society Research Professorship in 1999. Dr. Karin was elected to the National Academy of Sciences in 2005. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).
Scott E. Kern, M.D., Professor of Oncology, Johns Hopkins University, Baltimore, MD,
co-director of the Kimmel Cancer Center Gastrointestinal Cancer Program, Everett and Marjorie Kovler Professor of Pancreas Cancer Research.
Dr. Kern is a molecular geneticist interested in the clonal mutations of cancer, especially pancreatic cancer. His laboratory identified the first human Smad gene, SMAD4, as well as the first cancer mutations in Smad4, BRCA2, and other genes. Current interests include pharmacogenomics, mitotic instability, and the clinical significance of cancer biomarkers.
Guido Kroemer, Research Director, INSERM, Paris, France
John S. Lazo, PhD, Harrison Distinguished Professor, Departments of Pharmacology & Chemistry, Associate Director for Basic Science, UVA Cancer C Adjunct Professor Virginia Tech Carilion Research Institute
Arnold J. Levine, Ph.D. member of the National Academy, Professor, The Simons Center for Systems Biology in the School of Natural Sciences at the Institute for Advanced Study, Princeton, NJ.
Levine was on the faculty of the Biochemistry Department of Princeton University from1968 to 1979, when he became chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine. Returning to Princeton University in 1984, he was named Harry C. Wiess Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996.
He was President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. The recipient of many honors including: the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000); the Keio Medical Science Prize of the Keio University Medical Science Fund, Japan (2000);
the Albany Medical Center Prize in Medicine and Biomedical Research (2001); and the Award for Basic Research from the Surgical Society of Oncologists (2003).
Levine is a member of the National Academy of Sciences and of the Academy's Institute of M
he is also the author or coauthor of over 300 scientific papers, as well as a book, Viruses (1993).
He has served as board member or adviser to numerous scientific organizations and educational institutions, among them the N.J. Biotechnology Institute, the American Cyanamid Corporation, the SUNY Health Sciences Center in Brooklyn, Albert Einstein College of Medicine, the Weizmann Institute, the Huntsman Cancer Center of the University of Utah, and the Institute for Cancer Research in Lausanne, Switzerland.
Professor Lisanti, M.D., Ph.D. serves as the Director of the Manchester Breakthrough Breast Cancer Research Unit and holds the Muriel Edith Rickman Chair of Breast Oncology within the Institute of Cancer Sciences. He is also Professor of Cancer Biology and the new founding Director of the Manchester Centre for Cellular Metabolism (MCCM).
Dr. Melino is Full Professor of Molecular Biology at the University of Rome &Tor Vergata& in Italy.
He also currently works as Programme Leader for the Medical Research Council Toxicology Unit, in Leicester, UK.
Harold L. Moses, PhD, Professor, Vanderbilt-Ingram Cancer Center, Nashville, TN
Dr. Nakamura received his MD and PhD from Osaka University, and became Head of the Biochemistry Department, at the Cancer Institute, Japanese Foundation for Cancer Research in 1989. He was appointed as a professor at the Institute of Medical Science, University of Tokyo in 1994 and the Department of Medicine at the University of Chicago in 2012. From January to December 2011, Dr. Nakamura was Special Advisor to the Cabinet Secretary General, Office of Medical Innovation, Cabinet Secretariat, Government of Japan.
Dr. Nakamura received the Keio Medical Science Prize and the Tomizo Yoshida Award of the Japanese Cancer Association. He is a member of the Association of American Physicians.
Dr. Yusuke Nakamura discovered the APC (Familial Adenomatous Polyposis) tumor suppressor. Dr. Nakamura plays the leading role in the field of personalized medicine. He authored 1200 scientific articles.
Joseph Nevins, PhD, Professor, Duke University, Durham, NC
Pier Paolo Pandolfi, PhD, Professor, Harvard Medical School, Boston, MA
Nickolas Papadopoulos, Ph.D. Associate Professor, Department of Oncology, Director of Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions, CRB1, Room 585, 1650 Orleans Street, Baltimore, MD 21231
Arthur B. Pardee, Ph.D, member of the National Academy of Sciences, Professor of Biological Chemistry and Molecular Pharmacology Emeritus, Harvard Medical
Jeffrey Pollard, PhD, Professor, Albert Einstein College of Medicine, Bronx, NY
Carol Prives, Ph.D, member of the National Academy of Sciences, Professor, Columbia University, New York, NY
Edward V. Prochownik, MD, PhD, Professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Director of Oncology Research, Children's Hospital of Pittsburgh, PA
Neal Rosen, M.D., Ph.D.
is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical
Dr. John C. Reed, M.D., Ph.D. has been the Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 2, 2013. He is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida, and in San Diego State&University's Biology department.
Neal Rosen, Sloan-Kettering Cancer Center, New York, NY
Andrew V. Schally won the Nobel Prize for Medicine or Physiology in 1977, for his research into peptide hormone production in the brain. He is currently Distinguished Medical Research Scientist of the Department of Veterans Affairs, Head of the Endocrine, Polypeptide and Cancer Institute Veterans Affairs Medical Center, Research Service Miami, FL and South Florida VA Foundation for Research and Education, Distinguished Leonard Miller Professor of Pathology, Professor Division of Hematology/Oncology and Division of Endocrinology Department of Medicine, Miller School of Medicine, University of Miami, FL.
Dr. Schally was one of a pair of scientists to first isolate several of the communicating chemical links between the brain and the pituitary gland and also determined their structure and succeeded in synthesizing them. Schally&s discoveries have led to many practical clinical applications that are in wide use. He has written over 2,200 publications, more than 1,200 of them since receiving the Nobel Prize. 27 European & South American Universities: M.D.H.C., D.H.C., D.Sc.H.C., D.Nat. Sc. H.C.
Lasker Award 1975
Nobel Prize in Physiology or Medicine, 1977
Gregg L. Semenza, M.D., Ph.D, member of the National Academy of Sciences, Professor, Johns Hopkins University School of Medicine, Baltimore, MD
Jeff Settleman, Harvard Medical School, Boston, MA
Donald L. (Skip) Trump, MD, FACP, is CEO and executive director of Inova Schar Cancer Institute. Prior to joining Inova, Dr. Trump was president and CEO of Roswell Park Cancer Institute in Buffalo, NY.
Alexander Varshavsky, Ph.D, member of the National Academy of Sciences, Professor, California Institute of Technology, Pasadena, CA
Alexander Varshavsky is a recipient of the Albert Lasker Award for Basic Medical Research, the Wolf Prize in Medicine and the Louisa Gross Horwitz Prize from Columbia University in 2001 for his research on ubiquitination. In 2006 he won the March of Dimes Prize in Developmental Biology and he won the 2007 $1 million Gotham Prize for an original approach to killing cancer cells.
Bert Vogelstein, M.D., member of the National Academy of Sciences, Professor, Johns Hopkins University, Baltimore, MD
Bert Vogelstein is a Howard Hughes Medical Institute investigator.
He has received the Gairdner Foundation International Award, Louisa Gross Horwitz Prize from Columbia University, Prince of Asturias Award for Technical and Scientific Research, and other awards for his research.
Peter K. Vogt, Ph.D, member of the National Academy of Sciences Professor, The Scripps Research Institute, La Jolla, CA
Dr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California. He has received many awards and honors, including the Gregor Johann Mendel Medal, Charles S. Mott Prize, Ernst Jung Prize for Medicine, Bristol Meyers Award, and ICN International Prize in Virology. Dr. Vogt has been invited as a distinguished lecturer by more than twenty leading research institutions in the US, Europe, and Asia, among them the German Cancer Research Center in Heidelberg for the Meyenburg Foundation Lecture, the Princess Takamatsu Foundation, the Alexander von Humboldt Foundation of the Federal Republic of Germany and the Agency for Science, Technology and Research of Singapore. He was also elected an Honorary Member of the Japanese Cancer Association and received an honorary doctorate from the University of Würzburg. Dr. Vogt is an elected member of many prestigious academies, including the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology. He is the recipient of the 5th Annual Szent-Gy?rgyi Prize for Progress in Cancer Research.
Paul Workman, The Institute of Cancer Research, London, UK
Dr. Zeng Yixin, Professor and Director, Cancer Center and the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, China.&
He was elected as a member of the Chinese Academy of Sciences in 2005. Besides, Professor Zeng also has many other academic positions including the Vice President of the China Anti-Cancer Association, President of the Board of the International Society on Epstein-Barr Virus & Related Diseases (), a member of the Third World Academy of Sciences, and a member of the Europe-Asian Academy of Sciences
Since 2013, 4 members of Oncotarget// won : Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge
Oncotarget
Oncotarget Further Increases Its Publication Frequency
Due to rising importance, impact, volume and quality, Oncotarget will begin publishing two issues per week on Tuesday and Friday.
To accelerate the dissemination of highly important scientific information, all accepted papers will be included directly to final paginated issues to be released to PubMed quickly and in their permanent form.
Issues 8(31-42) are now in PubMed. Please see the .
Issues 8(43-46) are currently submitting and processing by the National Library of Medicine to appear in PubMed.
By submitting two issues per week we will cover the gap and there will be no delays in the future.
New Impact factor (IF) is 5.168
Oncotarget
Mol Cell Biol
Sci Reports
BMC Cancer
According to MEDLINE statement on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."
Featured articles by DR Lowy, the acting director of the NCI ():
Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.
Oncotarget. 2016 Jul 19;7(29):.
Tripathi BK, Lowy DR.
Oncotarget. 2017 Apr 25;8(17):.
Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more
Impact factor (IF) Thomson Reuters JCR
Total Cites
: 5-Year Impact Factor: 5.415
Scopus/SJR ranking:
2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology
Oncotarget ranks number 1 on Total Documents () among ,
If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.
Oncotarget is an outstanding and most important journal in the field of oncology and cancer research. Oncotarget is performing an extremely useful function for those of us working not only in cancer research, but also on other important topics in the field of medicine. Oncotarget deserves a strong support from investigators working in the area of oncology as well as from NIH.
-- Andrew V. Schally, member of the Editorial Board
Nobel Prize in Physiology or Medicine, 1977
Members of Editorial Board
have published 27 and 10 papers in Oncotarget
250 Plus Papers from the Editorial Board:
Copyright & 2017 Impact Journals Impact Journals is
a registered trademark of Impact Journals, LLC